DBV Technologies Newsroom

DBV Technologies Rating Suspended at Goldman Sachs

TipRanksOct 25 15:20 ET

Kepler Capital Sticks to Their Buy Rating for DBV Technologies (0QAJ)

TipRanksOct 24 21:54 ET

DBV Technologies Is Maintained at Buy by HC Wainwright & Co.

Dow JonesOct 24 05:41 ET

DBV Technologies Analyst Ratings

BenzingaOct 24 05:34 ET

DBV Technologies Analyst Ratings

BenzingaSep 24 09:58 ET

JMP Securities Maintains DBV Technologies(DBVT.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsSep 24 02:31 ET

JMP Securities Maintains DBV Technologies(DBVT.US) With Buy Rating, Maintains Target Price $5

Moomoo NewsSep 23 19:31 ET

Buy Rating Affirmed for DBV Technologies on Strong VITESSE Trial Progress and FDA Collaboration

TipRanksSep 23 19:00 ET

Kepler Capital Sticks to Their Buy Rating for DBV Technologies (0QAJ)

TipRanksAug 1 21:54 ET

DBV Technologies Analyst Ratings

BenzingaJul 31 14:16 ET

JMP Securities Maintains DBV Technologies(DBVT.US) With Buy Rating, Cuts Target Price to $5

Moomoo NewsJul 31 01:32 ET

JMP Securities Sticks to Its Buy Rating for DBV Technologies SA – American (DBVT)

TipRanksJul 31 01:12 ET

DBV Technologies Analyst Ratings

BenzingaMay 8 15:23 ET

HC Wainwright & Co. Maintains Buy on DBV Technologies, Lowers Price Target to $5

BenzingaMay 8 15:22 ET

Optimistic Buy Rating for DBV Technologies With Viaskin's Market Potential and Regulatory Prospects

TipRanksMay 8 06:31 ET

Buy Rating Affirmed for DBV Technologies SA Amidst Strong Clinical Progress and Solid Financial Footing

TipRanksMay 8 01:00 ET

Buy Rating Affirmed for DBV Technologies on Viaskin Patch Development and Positive Trial Outcomes

TipRanksMar 8 06:35 ET

Positive Clinical and Financial Projections for DBV Technologies Reinforce Buy Rating

TipRanksMar 8 00:35 ET

Buy Rating Affirmed for DBV Technologies on Strong Viaskin Peanut Patch Clinical Data and Promising Trials

TipRanksFeb 26 00:25 ET

DBV Technologies Analyst Ratings

BenzingaFeb 21 06:46 ET